Twenty-four Staphylococcus species or subspecies were examined for their susceptibilities to the fluoroquinolone fleroxacin (Ro 23-6240) by disk diffusion (5-jig disk) and by agar dilution for the determination of MICs.
Fleroxacin (Ro 23-6240) is a new orally and intravenously administered trifluoroquinolone with a half-life of 9 to 10 h in humans and peak levels of 2.3 VLg/ml in serum after a single 200-mg oral dose (12) . The drug has shown excellent activity against most members of the family Enterobacteriaceae, inhibiting 90% of isolates per species at concentrations of <1 p.g/ml (2, 3) . Because of its broad spectrum of activity, fleroxacin may also have use for treating staphylococcal infections; a previous report has shown the in vitro effectiveness of fleroxacin against two species of staphylococci (9) . In the current study, 24 Staphylococcus species or subspecies were tested for their susceptibilities to fleroxacin by disk diffusion and by agar dilution for determination of MICs. The resistant strains were further tested for their susceptibilities to oxacillin and to the fluoroquinolone ciprofloxacin.
(A preliminary report of this work was presented previously [1] .)
Reference strains of the 24 Staphylococcus species or subspecies were obtained from our laboratory's collection of isolates from the skin of healthy human volunteers or from animals. Clinical strains used in this study were isolated from April 1989 to February 1990 from a variety of patients at Rex Hospital, Raleigh, N.C. All the clinical strains were identified by using the criteria of Kloos and coworkers (4, 5) . The reference and clinical strains were maintained on P agar (11) (3) . Criteria for susceptibilities to oxacillin and ciprofloxacin were those recommended by the National Committee for Clinical Laboratory Standards (7, 8) .
A total of 338 reference strains of staphylococci were analyzed for their susceptibilities to fleroxacin (Table 1) . The novobiocin-resistant species Staphylococcus saprophyticus, S. xylosus, S. cohnii, S. arlettae, S. kloosii, and S. gallinarum demonstrated an intrinsic intermediate susceptibility (MIC, 4 jig/ml; zone of inhibition, 16 to 19 mm) and were less susceptible to fleroxacin than were the novobiocin-susceptible species (MIC, 0.5 to 2.0 jig/ml; zone of inhibition, 21 to 27 mm). The novobiocin-resistant species were also more resistant to the fluoroquinolone ciprofloxacin than were the novobiocin-susceptible species; however, on the basis of the recommended cutoff points, they were just included in the susceptible category. DNA gyrase is a common target for novobiocin and the fluoroquinolones; this fact may account for the related responses of these species.
A total of 478 clinical strains of staphylococci were analyzed for their susceptibilities to fleroxacin (Table 1) . However, six isolates of S. haemolyticus were found to be members of three different strains on the basis of antibio- grams, biochemical reactions, colony morphologies, and plasmid compositions. The clinical strains were generally less susceptible to fleroxacin than were reference strains isolated from the skin of healthy volunteers. The MIC range for clinical strains was c0.25 to 32 ,xg/ml, whereas that for reference strains was '0.25 to 4 ,ug/ml. The differences in MICs are shown in Fig. 1 Fig. 2 . Strains of S. epidermidis accounted for the major errors in the correlation between disk diffusion and MIC results. One likely source of error may be due to the difficulty in suspending adherent strains of S. epidermidis in aqueous solutions. The isolates resistant to fleroxacin were well distributed between inpatients and outpatients, and there were no clusters of infection noted within the hospital.
The resistant strains of S. epidermidis, S. haemolyticus, S. hominis, and S. warneri were analyzed for their susceptibilities to oxacillin and ciprofloxacin. Of the 23 fleroxacinresistant strains of S. epidermidis, 17 strains (77%) were oxacillin resistant and 11 strains (50%) were ciprofloxacin resistant. Of the 22 fleroxacin-resistant strains of S. haemolyticus, 21 strains (95%) were oxacillin resistant and 17 strains (77%) were ciprofloxacin resistant, while 23% had intermediate susceptibility to ciprofloxacin. All three fleroxacin-resistant strains of S. hominis were oxacillin susceptible, and one strain showed resistance to ciprofloxacin. The fleroxacin-resistant strain of S. warneri was susceptible to both oxacillin and ciprofloxacin. The fleroxacin-resistant strains of S. epidermidis and S. haemolyticus made up 16.5 and 56.8% of the total number of oxacillin-resistant strains of that species, respectively. We conclude that fleroxacin is an effective antimicrobial agent against most staphylococci. However, in vitro tests indicate that in a clinical setting resistant strains of S. haemolyticus and S. epidermidis are being selected, and in several other species strains with reduced susceptibilities are being selected.
